These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 25390554

  • 1. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
    Khagi S, Saif MW.
    Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
    [Abstract] [Full Text] [Related]

  • 2. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
    Raj N, Reidy-Lagunes D.
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
    [Abstract] [Full Text] [Related]

  • 3. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A, Bodoky G.
    Orv Hetil; 2011 Mar 06; 152(10):379-91. PubMed ID: 21354954
    [Abstract] [Full Text] [Related]

  • 4. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L, Schwarz RE.
    Curr Mol Med; 2013 Mar 06; 13(3):333-9. PubMed ID: 23331005
    [Abstract] [Full Text] [Related]

  • 5. Everolimus for the treatment of pancreatic neuroendocrine tumors.
    Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P.
    Expert Opin Pharmacother; 2012 Oct 06; 13(14):2073-84. PubMed ID: 22873789
    [Abstract] [Full Text] [Related]

  • 6. Medical treatment of neuroendocrine tumours.
    Weber HC.
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb 06; 20(1):27-31. PubMed ID: 23221494
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N, Reidy-Lagunes D.
    Pancreas; 2014 Nov 06; 43(8):1185-9. PubMed ID: 25333401
    [Abstract] [Full Text] [Related]

  • 11. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA, Kim M, Wenger SD, O'Bryant CL.
    Ann Pharmacother; 2012 Sep 06; 46(9):1212-9. PubMed ID: 22947595
    [Abstract] [Full Text] [Related]

  • 12. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F, Rizzo M, Festino L, Ambrosio F, Molino C, Uomo G, Cartenì G.
    Expert Opin Ther Targets; 2012 Apr 06; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [Abstract] [Full Text] [Related]

  • 13. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG, Strosberg JR, Halfdanarson TR.
    Oncology; 2012 Apr 06; 83(3):117-27. PubMed ID: 22797357
    [Abstract] [Full Text] [Related]

  • 14. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
    Wolin EM.
    Cancer Lett; 2013 Jul 10; 335(1):1-8. PubMed ID: 23419523
    [Abstract] [Full Text] [Related]

  • 15. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F.
    Cancer Treat Rev; 2010 Nov 10; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [Abstract] [Full Text] [Related]

  • 16. Update on novel therapies for pancreatic neuroendocrine tumors.
    Oberstein PE, Saif MW.
    JOP; 2012 Jul 10; 13(4):372-5. PubMed ID: 22797392
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An update on the management of pancreatic neuroendocrine tumors.
    Gao L, Natov NS, Daly KP, Masud F, Chaudhry S, Sterling MJ, Saif MW.
    Anticancer Drugs; 2018 Aug 10; 29(7):597-612. PubMed ID: 29782352
    [Abstract] [Full Text] [Related]

  • 19. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S, de Braud F, Concas L, Bregant C, Leuzzi L, Formisano B, Buzzoni R.
    Tumori; 2014 Aug 10; 100(6):e286-9. PubMed ID: 25688512
    [Abstract] [Full Text] [Related]

  • 20. Recent studies show promise for treating rare pancreatic tumors.
    Peres J.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):624-7. PubMed ID: 21474831
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.